Peer-influenced content. Sources you trust. No registration required. This is HCN.
ReachMD
Explore the complexities of recently found pathomechanisms, cutting-edge research on emergent molecular pathways, and thorough insights into novel treatment options.
Psychiatry August 2nd 2023
Dana-Farber Cancer Institute
The field of gastric and esophageal cancer treatment is witnessing remarkable advancements through targeted therapies and immunotherapies. Explore the latest clinical trials and discoveries that are redefining the standard of care for these traditionally difficult-to-treat cancers.
Gastroenterology August 1st 2023
The New England Journal of Medicine
Uncover the potential of dupilumab in managing COPD patients with type 2 inflammation as this Phase 3 trial reveals fewer exacerbations, improved lung function, and enhanced life quality among the treated cohort.
Allergy & Immunology July 27th 2023
Cancer Therapy Advisor
Innovations in mRCC management are accelerating, and significant shifts have already begun with the ODYSSEY RCC study and the first-ever comprehensive ASCO guidelines for metastatic clear-cell RCC – read on to stay ahead of the curve.
Nephrology July 25th 2023
NEJM Evidence
Recent advancements in AI are driving personalized treatment approaches for localized prostate cancer. This study highlights an AI-based model that could guide the application of ADT with radiotherapy, refining treatment strategies and improving patient outcomes.
Oncology, Medical July 10th 2023
Clinicians are eyeing the increased survival odds associated with Tagrisso, a targeted therapy for early-stage NSCLC patients. This revelation may shift the narrative on post-operative treatment protocols, promoting wider acceptance in oncological circles.
Oncology, Medical June 20th 2023